Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Regeneron Pharmaceuticals Inc REGN

Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:REGN)

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

GlobeNewswire 10 days ago

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

GlobeNewswire 12 days ago

Regeneron Announces Investor Conference Presentations

GlobeNewswire November 11, 2024

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

GlobeNewswire November 6, 2024

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Business Wire November 4, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Business Wire November 4, 2024

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Business Wire November 1, 2024

Regeneron Reports Third Quarter 2024 Financial and Operating Results

GlobeNewswire October 31, 2024

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

GlobeNewswire October 24, 2024
View More News ››

Opinion & Analysis (NDAQ:REGN)

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Streetwise Reports March 18, 2020

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Streetwise Reports September 24, 2019

Phase 3 trial for Inovio's VGX-3100 in cervical dysplasia gets FDA go-ahead

The Life Sciences Report June 16, 2017

Inovio moves forward on brain cancer and cancers caused by HPV; Zika and Ebola vaccines also advance

The Life Sciences Report May 18, 2017

Why the election is not as relevant to drug stocks as you might believe

The Life Sciences Report November 4, 2016

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016
View More Opinion ››

Bullboard Posts (NDAQ:REGN)

REGN Price Target Alert: $1,077.00. Issued by Leerink Partne

News; $REGN REGN Price Target Alert: $1,077.00. Issued by Leerink Partners2024-09-24 07:00:09 ET David Risinger from Leerink Partners...
whytestocks - September 24, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): A Diversified

http://beyondspx.com/2024/07/31/regeneron-pharmaceuticals-inc-nasdaqregn-a-diversified-powerhouse-delivering-consistent-growth/
MikeTester - August 2, 2024

Just added REGN

Just added 1/2 position of REGN.   Will add a few more next month.
Mmb060 - April 20, 2023

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020

TRUMPS TIMELINE

https://www.channelchek.com/news-channel/The_Timing_of_a_COVID_Vaccine
SmallCapPaul - October 6, 2020
View more Bullboard ››

Trillion Energy International Inc.

Trillion Energy International Inc.

Trillion Energy International Inc. is a Canada-based oil and gas producing company that strives to maximize shareholder value ...
View More »